In the last Parallax episode of the year,Dr Ankur Kalra welcomed back Dr Sukh Nijjer, Interventional Cardiologist from Imperial College London, to review the most impactful events and advances in cardiology from 2021.
This year we had a number of studies that helped clarify our understanding of the world of antiplatelets: First, Ankur and Sukh discuss the take-home messages from HOST-EXAM, a Korean study presented at ACC 2021. They discuss their clinical experiences within the UK and US setting. Next, Sukh talks about the STOPDAPT-2 ACS study, presented at ESC 2021. Sukh interprets the findings in the light of TWILIGHTand summarises his thoughts on the therapy.
2021 was not a great year for physiology: Sukh shares his take on FLOWER-MI, presented at ACC 2021. He offers a deep dive into the data and highlights both the importance of the findings and the limitations of the study.
Next, they discuss RIPCORD 2 from ESC 2021 and finally, Sukh highlights the findings from the FAME 3 trial.
What is the importance of genotype testing in the world of antiplatelets? What are the considerations for clinicians? Should we stop using FFR? How can we incorporate novel findings to patient care? What are the practical considerations that we should take into account when looking at the physiology trials of 2021?
Stay tuned for Part 2 - heart failure and surgical trials coming in 2022.
Questions and comments can be sent to “podcast@radciffe-group.com” and may be answered by Ankur in the next episode. Guest @SukhNijjer, hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Brought to you by Edwards: www.edwardstavr.com
Rohin shares an advice that he received at the beginning of his career: “If you can deal with an average day, the exciting day will take care of itself.”
Ankur asks Rohin about Medlife Crisis and the work that goes into producing a show followed by 500K people. Rohin reiterates his passion for research and science communication. Ankur and Rohin discuss what it means to be yourself on social media and what is Rohin’s advice to our early-career listeners.
In this information-packed episode, Dr Patel takes us behind the scenes and talks about the work that goes into the curation of the programme and the considerations that shape the event. Dr Kalra asks Dr Patel about his highlights over the years and the movement and changes that he observed as vice chair and chair of the event. Dr Patel elaborates on the key late-breaking science trials in 2022. Dr Kalra and Dr Patel discuss the grading system of the award applications and share some useful information with our listeners.
Exploring Art & Advancement Within Medicine - A Conversation with an Interventional Cardiologist.
Dr. Ankur Kalra invites Dr Salim S Virani to help simplify the concept of Lp(a) with answering key questions about its measurement and its place in practice and prevention.
Dr Khan talks about education in the US and his decision to move back to Pakistan. Ankur asks Sohail about his new professional home: NICVD, a free clinic providing primary heartcare for Pakistanis. They discuss some of the innovations Dr Khan works on to improve patient care that utilise simple but effective interventions. We learn more about free screening clinics and about Dr Khan’s work on the largest ever study in Pakistan on association of Lpa and CV disease in South Asians.
